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Abstract
7KHSURLQIODPPDWRU\F\WRNLQH,/ȖLVKLJKO\H[SUHVVHGLQHSLWKHOLDOFHOOVDQGLVDSLYRWDOPHGLDWRU
RI HSLWKHOLDO LQIODPPDWLRQ ,Q SDUWLFXODU ,/Ȗ LV VWURQJO\ DVVRFLDWHG ZLWK WKH LQIODPPDWRU\ VNLQ
GLVHDVHSVRULDVLV$VZLWKRWKHU,/F\WRNLQHV,/ȖLVH[SUHVVHGDVDQLQDFWLYHSUHFXUVRUDQGPXVW
be processed by specific proteases to become bioactive. Our aim therefore was to identify protease/s
FDSDEOH RI ,/Ȗ DFWLYDWLRQ DQG H[SORUH WKH LPSRUWDQFH RI WKLV DFWLYDWLRQ LQ SVRULDVLV 8VLQJ D
keratinocyte-based activity assay in conjunction with small-molecule inhibitors and siRNA gene
VLOHQFLQJFDWKHSVLQ6ZDVLGHQWLILHGDVWKHPDMRU,/ȖDFWLYDWLQJSURWHDVHH[SUHVVHGE\HSLWKHOLDO
cells. Interestingly, cathepsin S activity was strongly upregulated in samples extracted from psoriasis
SDWLHQWV UHODWLYH WR KHDOWK\ FRQWUROV ,Q DGGLWLRQ ,/Ȗ6HU LGHQWLILHG DV WKH PDLQ SURGXFW RI
FDWKHSVLQ 6GHSHQGHQW ,/Ȗ FOHDYDJH LQGXFHG SVRULDVLIRUP FKDQJHV LQ KXPDQ VNLQHTXLYDOHQW
PRGHOV7RJHWKHUWKHVHGDWDSURYLGHLPSRUWDQWPHFKDQLVWLFLQVLJKWVLQWRWKHDFWLYDWLRQRI,/ȖDQG
KLJKOLJKW WKDW FDWKHSVLQ 6PHGLDWHG DFWLYDWLRQ RI ,/Ȗ PD\ EH LPSRUWDQW LQ WKH GHYHORSPHQW RI
QXPHURXV,/ȖGULYHQSDWKRORJLHVLQDGGLWLRQWRSVRULDVLV
Significance statement
,/Ȗ LV D SRWHQW F\WRNLQH ZKLFK GULYHV DQG RUFKHVWUDWHV LQIODPPDWLRQ ,W LV VWURQJO\ H[SUHVVHG DW
barrier tissues such as the skin thus is particularly relevant to inflammatory diseases which affect
WKHVHWLVVXHVLQFOXGLQJSVRULDVLV,/ȖLVH[SUHVVHGDVDQLQDFWLYHSUHFXUVRUZKLFKUHTXLUHVSUHFLVH
N- terminal truncation for activation. In these investigations, we demonstrate that cathepsin S is the
PDMRU,/ȖDFWLYDWLQJSURWHDVHH[SUHVVHGE\EDUULHUWLVVXHV0RUHRYHUZHVKRZWKDWERWKFDWKHSVLQ
6DQG,/ȖDUHVWURQJO\XSUHJXODWHGLQSVRULDWLFLQIODPPDWLRQ7KHVHILQGLQJVDUHLPSRUWDQWDVWKH\
ERWK LGHQWLI\ WKH PHFKDQLVP RI ,/Ȗ DFWLYDWLRQ DQG KLJKOLJKW WKDW WKLV PHFKDQLVP PD\ SOD\ D
central role in the development of psoriatic inflammation.
Introduction
\body The interleukin (IL)-1 family cytokines are fundamental regulators of the innate immune
system, and orchestrate multiple inflammatory responses (1, 2). IL-1 cytokines are produced rapidly
following infection or injury, and are capable of potently inducing a range of beneficial pro-
inflammatory processes, including additional cytokine expression, antigen-presenting cell migration
and leukocyte activation and infiltration (3-5). The aberrant expression and regulation of IL-1
cytokines is associated with a broad range of immuopathologies, ranging from autoinflammatory to
autoimmune disorders (6-8). Therefore, a greater insight into the regulation and function of IL-1
cytokines is not only of academic interest, but also of significant therapeutic importance.
,/Į,/ȕDQG,/ȖDUHDJRQLVWLFF\WRNLQHVDQGWKHPRVWUHFHQWO\GLVFRYHUHGRIWKH,/IDPLO\
(9). Interestingly, there is growing evidence to suggest that these cytokines are important for the
development of several inflammatory disorders, including psoriasis (10). In psoriatic lesions, the IL-
36 cytokines have been shown to be amongst the most specific and highly up-regulated mRNAs
relative to other inflammatory skin diseases and healthy controls (11-13). Moreover, hypomorphic
mutations in the IL-36 receptor antagonist (IL-36Ra) cause the severe and potentially lethal subtype
of psoriasis called pustular psoriasis in a number of cohorts (14, 15). Mouse models further support
these observations, showing that IL-36 overexpression in keratinocytes results in a transient
inflammatory skin condition resembling psoriasis (16). In addition, IL-36 receptor-deficient mice
have been found to be resistant to Imiquimod-induced psoriasiform dermatitis (17). Interestingly,
recent studies have also demonstrated a role for the IL-36 receptor in mucosal wound healing,
suggesting that IL-36 cytokines have an important physiological role in epithelial repair and
homeostasis, as well as the more established, pathological role in the initiation and maintenance of
psoriatic inflammation (18).
Unlike many other cytokines, IL-1 family members are expressed without a signal peptide and
therefore are not secreted via the classical secretory pathway (19). In addition, most IL-1 cytokines
are expressed as inactive precursors and must be processed to become biologically active (20). The
DFWLYDWLRQRI,/ȕDQG,/IRULQVWDQFHLVGHSHQGHQWXSRQFDVSDVHDSURWHRO\WLFHQ]\PHWKDWLV
regulated by large multiprotein inflammasome complexes (21, 22). This cascade can be induced by a
range of endogenous and exogenous triggers and serves as an important sensor of danger (23). In
FRQWUDVW,/ĮGRHVQRWFRQWDLQDFDVSDVHFOHDYDJHPRWLIDQGLVLQVWHDGSURFHVVHGE\WKHFDOFLXP
dependent protease calpain (24). In short, these IL-1-processing proteases are central to the activation
of IL-1 family cytokines and thus are essential mediators of inflammation. In a previous report it was
demonstrated that a precise N-terminal truncation (9 amino acids upstream of a conserved A-X-D
PRWLIZDVDOVRUHTXLUHGIRU,/Į,/ȕDQG,/ȖWRJDLQELRORJLFDODFWLYLW\25). Specifically,
DFWLYDWLRQRI,/ĮZDVGHPRQVWUDWHGZKHQFOHDYHGDWDPLQRDFLG.,/ȕDW5DQG,/ȖDW
S18. In these in vitro studies, precise cleavage was found to increase receptor affinity over 10,000
fold, suggesting that processing is likely to be significant in an in vivo setting.
Given the potential importance of IL-36 cleavage in epithelial biology, there is a large and growing
interest in the proteases that drive IL-36 processing. There is a particular focus on IL-36-activating
proteases in the context of psoriatic inflammation, where the therapeutic potential is evident (26). IL-
ȖLVRISDUWLFXODULQWHUHVWKHUHDVWKLVF\WRNLQHLVWKHRQO\,/F\WRNLQHFRQVWLWXWLYHO\H[SUHVVHGLQ
the skin (13), and is the most strongly up-regulated in psoriasis plaques (12). In a recent report by
Henry et al, it was found that the neutrophil-derived proteases neutrophil elastase and proteinase 3
ZHUH FDSDEOH RI DFWLYDWLQJ ,/Ȗ 27). Although the findings of this report are of interest, the
H[SUHVVLRQRIWKHVH,/ȖDFWLYDWLQJSURWHDVHVE\QHXWURSKLOVZRXOGOLNHO\EHOLPLWHGWRVLWHVRIDFXWH
LQIODPPDWLRQ)XUWKHUPRUHGHVSLWHQHXWURSKLOSURWHDVHVJHQHUDWLQJ,/ȖDFWLYLW\WKHVWXG\VKRZHG
WKDW WKH PDMRULW\ RI FOHDYDJH E\ QHXWURSKLO SURWHDVHV JHQHUDWHG LQDFWLYH IRUPV RI ,/Ȗ DQG RQO\
minor undetectable amounts of bioactive cytokines were responsible for activity. Due to their lack of
specificity and expression profile, it is therefore unlikely that these proteases represent the major
SURFHVVRUV RI ,/Ȗ ZLWKLQ EDUULHU WLVVXHV ,Q WKLV VWXG\ ZH VKRZ WKDW ,/Ȗ SURFHVVLQJ LV
independent of caspase-1 and that the cysteine protease cathepsin S precisely cleaves and activates IL-
Ȗ%RWKLQWUDFHOOXODUDQGVHFUHWHGH[WUDFHOOXODUFDWKHSVLQ6DFWLYLW\ZDVGHWHFWDEOHLQDUDQJHRIVNLQ
resident cells, including fibroblasts and keratinocytes, suggesting that this protease represents the
PDMRUUHJXODWRURI,/ȖDWEDUULHUWLVVXHV)XUWKHUPRUHLWZDVDOVRVKRZQWKDWFDWKHSVLQ6OHYHOVDQG
DFWLYLW\DUHHOHYDWHG LQSVRULDWLFVNLQ OHVLRQVDQG WKDW ,/Ȗ6HU6 WKHSURGXFWRIFDWKHSVLQ6
GHSHQGHQW ,/Ȗ SURFHVVLQJ GULYHV K\SHUNHUDWRVLV LQ VNLQ HTXLYDOHQWV 7RJHWKHU WKHVH GDWD
GHPRQVWUDWH WKDW WKH SUHFLVH FOHDYDJH RI ,/Ȗ E\ FDWKHSVLQ 6 LV FULWLFDO LQ WKH DFWLYDWLRQ RI LWV
bioactivity, and that this processing may be pivotal in the generation of a psoriatic phenotype.
Results
(SLWKHOLDOFHOOGHULYHGSURWHDVHVDFWLYDWH,/Ȗ
,QLWLDOH[SHULPHQWVFRQILUPHGWKDWWKHDGGLWLRQRIWUXQFDWHG,/Ȗ,/Ȗ6LQGXFHVWKHVHFUHWLRQ
of the pro-inflammatory cytokine IL-8 in a human keratinocyte cell line (HaCaT cells; Fig 1A). In
FRQWUDVW WKH DGGLWLRQ RI IXOOOHQJWK ,/Ȗ ,/Ȗ )/ KDG QR HIIHFW RQ ,/ OHYHOV VXSSRUWLQJ
previous evidence suggesting that IL-36 cytokines require processing to elicit their pro-inflammatory
activity (25). These effects were shown to be IL-36 dependent as they were ablated by addition of the
IL-36 receptor antagonist (Ra). Importantly, these results also validate the use of HaCaT cells as a
ELRDVVD\IRUPHDVXULQJ,/ȖSURFHVVLQJ
,WLVZHOOHVWDEOLVKHGWKDWRWKHU,/F\WRNLQHVPRVWQRWDEO\,/ȕFDQEHFOHDYHGDQGDFWLYDWHGE\
caspase-1 (21 %\ LQFXEDWLQJ ,/Ȗ )/ RU 6802WDJJHG ,/Ȗ )/ ERWK SRO\KLVWLGLQH WDJJHG
with recombinant caspase-1, and then running the samples on an anti-His Western blot, it was
FRQILUPHGWKDWFDVSDVHGRHVQRWFOHDYH,/Ȗ)/RU6802WDJJHG,/Ȗ)/VXJJHVWLQJWKDWWKLV
FDVSDVH LV QRW FDSDEOH RI ,/Ȗ DFWLYDWLRQ )LJ % :KLOVW VRPH ,/DFWLYDWLQJ SURWHDVHV KDYH
been identified previously, we propose that these do not represent the major tissue resident activators
RI ,/Ȗ 5HFHQW HYLGHQFH VXJJHVWV WKDW ,/ F\WRNLQHV SOD\ LPSRUWDQW UROHV LQ LQIODPPDWRU\
UHVSRQVHVDWHSLWKHOLDOVXUIDFHV7KHUHIRUHZHK\SRWKHVLVHGWKDW,/ȖDFWLYDWLQJSURWHDVHVPD\DOVR
be expressed within the cells of such barrier tissues. To test this hypothesis, the epithelial cell line
A549 was lysed using a hypotonic buffer and incubated with HaCaTs for 24 hr. Neither the addition
RIWKHO\VDWHQRU,/Ȗ)/DORQHKDGDQHIIHFWRQ,/H[SUHVVLRQ)LJ&+RZHYHUZKHQERWKWKH
O\VDWH DQG ,/Ȗ )/ ZHUH DGGHG WRJHWKHU WKHUH ZDV D PRGHVW EXW VLJQLILFDQW LQFUHDVH LQ ,/
H[SUHVVLRQ VXJJHVWLQJ WKDW WKHUH DUH ,/ȖDFWLYDWLQJ SURWHLQV ZLWKLQ WKH O\VDWH ,PSRUWDQWO\ WKH
addition of IL-36Ra ablated this effect, demonstrating that the increase in IL-8 expression was due to
,/ȖDFWLYLW\
7RGHWHUPLQHWKHVXEFHOOXODUORFDOL]DWLRQRIWKH,/ȖSURFHVVLQJDFWLYLW\WKH$FHOOO\VDWHVZHUH
separated into cytosolic and lysosomal fractions and the activity assay was repeated. Firstly,
successful separation of cellular fractions was demonstrated by Western blot analysis. Here it was
shown that the cytosol fraction contained the cytosol marker GAPDH but not the lysosome marker
LAMP-1, whereas the lysosomal fraction contained LAMP-1 but not GAPDH (Fig.1D). In the
DFWLYLW\DVVD\H[SHULPHQWV WKHDGGLWLRQRIERWK ,/Ȗ)/DQG$F\WRVROKDGQRHIIHFWRQ ,/
OHYHOVVXJJHVWLQJWKDWWKH,/ȖSURFHVVLQJDFWLYLW\GLGQRWUHVLGHZLWKLQWKLVIUDFWLRQ)LJ(,Q
FRQWUDVWWKHDGGLWLRQRIERWKWKHO\VRVRPDOIUDFWLRQDQG,/Ȗ)/FDXVHGDVWURQJDQGVLJQLILFDQWXS
UHJXODWLRQLQ,/VHFUHWLRQUHODWLYHWRERWK,/Ȗ)/DORQHDQGO\VRVRPHDORQHWUHDWHGFHOOV$JDLQ
this effect was almost completely ablated when IL-36Ra was added, excluding non-specific effects on
,/ VHFUHWLRQ 7R LQYHVWLJDWH ZKHWKHU WKHUH LV ,/ȖSURFHVVLQJ LQ RWKHU FHOO W\SHV WKH DERYH
experiment was repeated using lysosomal fractions from HaCaT cells (Fig. 1F), primary human
fibroblasts (Fig. 1G) and keratinocytes (Fig. 1H). As observed with A549 cells, the incubation of cells
ZLWK ERWK ,/Ȗ )/ DQG O\VRVRPH FDXVHG D VLJQLILFDQW DQG ,/VSHFLILF XSUHJXODWLRQ LQ ,/
VHFUHWLRQUHODWLYHWRVDPSOHVWUHDWHGZLWK,/Ȗ)/RUO\VRVRPHDORQH7RJHWKHUWKHVHGDWDKLJKOLJKW
WKDW,/ȖDFWLYDWLQJF\WRNLQHVDUHH[SUHVVHGXELTXLWRXVO\DWOHDVWZLWKLQWKHO\VRVRPHVRIFHOOVLQ
barrier tissues.
$FWLYDWLRQRI,/ȖLVGHSHQGHQWRQFDWKHSVLQ6
The lysosome contains a broad range of proteases, most of which are either serine or cysteine
proteases (28). To identify the IL-36Ȗactivating protease, the class of this protease was first
determined using broad-range molecular inhibitors. As previously shown, the incubation of HaCaT
FHOOVZLWKERWK,/Ȗ)/DQG$FHOOO\VRVRPHFDXVHGDVLJQLILFDQWLQFUHDVHLQ,/VHFUHWLRQ)LJ
2A). Whilst this IL-8 secretion was unaffected by addition of the serine protease inhibitor AEBSF, IL-
8 secretion was almost completely ablated by the addition of the cysteine protease inhibitor E64.
,PSRUWDQWO\(KDGQRHIIHFWRQ,/Ȗ6LQGXFHG,/VHFUHWLRQGHPRQVWUDWLQJWKDWWKHLQKLELWRU
does not simply inhibit IL-8 secretion. Thus, it was concluded that the IL-36Ȗactivating lysosomal
protease is a cysteine protease/s.
In the activity assay used, HaCaT cells were cultured in a neutral buffered media and therefore the IL-
36Ȗactivating lysosomal protease must be both stable and active at pH 7. Whereas most lysosomal
cysteine proteases only function at an acidic pH, cathepsin S can function at a neutral pH (29) and so
this protease was identified as a candidate IL-36Ȗactivating lysosomal protease. To test this, HaCaT
FHOOVZHUHLQFXEDWHGZLWK$FHOOO\VRVRPHDQG,/Ȗ)/ERWKLQWKHDEVHQFHDQGSUHVHQFHRIWKH
VSHFLILFFDWKHSVLQ6LQKLELWRU&$76L,/VHFUHWLRQLQGXFHGLQUHVSRQVHWRO\VRVRPHDQG,/Ȗ)/
was completely abrogated by the addition of CATSi (Fig. 2B). Again, the inhibitor had no effect on
6LQGXFHG ,/ VHFUHWLRQ KLJKOLJKWLQJ WKDW WKH &$76L IXQFWLRQV WR LQKLELW ,/Ȗ )/ SURFHVVLQJ
specifically. To support these findings and rule out any non-specific effects of the CATSi, the activity
assay was repeated using lysosome extracted from A549 cells that had been transfected with cathepsin
S siRNA or scrambled siRNA. Downregulation of cathepsin S lysosomal protein expression in the
cathepsin S siRNA transfected cells was significant, relative to the scrambled siRNA control (Fig.
2C). Importantly, the downregulation in cathepsin S expression resulted in a strong and significant
GHFUHDVH LQ WKH O\VRVRPH DQG ,/Ȗ )/LQGXFHG ,/ VHFUHWLRQ DJDLQ UHODWLYH WR WKH VFUDPEOHG
VL51$FRQWURO)LJ'7KHUHIRUHWKHUHLVUREXVWHYLGHQFHWRVXJJHVWWKDWWKHDFWLYDWLRQRI,/Ȗ
by lysosomal proteases is dependent on cathepsin S.
6HFUHWHGFDWKHSVLQ6DFWLYDWHV,/Ȗ
It is well established that cathepsin S can be secreted by a range of different cell types. Thus, we
SRVWXODWHGWKDWFDWKHSVLQ6PD\DOVRIXQFWLRQH[WUDFHOOXODUO\ WRLQGXFH,/Ȗ)/DFWLYDWLRQ ,Q WKLV
investigation, cathepsin S was shown to accumulate in the supernatants of A549 cells, primary
keratinocytes and primary fibroblasts (Fig. 3A). To test whether this secreted cathepsin S could
DFWLYDWH,/ȖVXSHUQDWDQWVZHUHFROOHFWHGDQGDGGHGWR+D&D7FHOOV,QWKHVHH[SHULPHQWVP0
DTT was added to the supernatants to facilitate cathepsin S activity. Importantly, the addition of IL-
Ȗ)/WR'77VXSSOHPHQWHG2SWL0(0GLGQRWKDYHDQ\HIIHFWRQ,/SURGXFWLRQUHODWLYHWR'77
supplemented OptiMEM alone, highlighting that the de novo cathepsin S production by HaCaT cells
LVQRWVLJQLILFDQWHQRXJKWRDIIHFW,/VHFUHWLRQ)LJ%+HUHWKHDGGLWLRQRIERWK,/Ȗ)/ZLWK
either A549 cell conditioned media (Fig. 3B), keratinocyte conditioned media (Fig. 3C) or fibroblast
conditioned media (Fig. 3D) caused an increase in IL-8 secretion, relative to IL-8 secretion induced
E\ WKH DGGLWLRQRIFRQGLWLRQHGPHGLD DORQH7KHVHGDWD LQGLFDWH WKDW WKHUH LV ,/Ȗ)/SURFHVVLQJ
activity within the secretome of A549 cells, primary keratinocytes and primary fibroblasts. Of note,
activity was ablated by the addition of IL-36Ra, proving that the increase in IL-8 secretion was
VSHFLILFDOO\GXHWRWKHSURFHVVLQJRI,/Ȗ)/
7RGHWHUPLQHZKHWKHUWKLVH[WUDFHOOXODU,/Ȗ)/SURFHVVLQJDFWLYLW\ZDVGHSHQGHQWRQFDWKHSVLQ6
A549 cells were transfected with cathepsin S siRNA or scrambled siRNA. Downregulation of
cathepsin S protein levels were observed in the supernatant of the cathepsin S siRNA transfected
cells, and were found to be significantly lower than cathepsin S levels in supernatants extracted from
the scrambled siRNA treated cells (Fig. 3E). Importantly, the downregulation of cathepsin S resulted
LQ D VWURQJ DQG VLJQLILFDQW GHFUHDVH RI ,/ VHFUHWLRQ LQGXFHG E\ ,/Ȗ )/ LQ FRPELQDWLRQ ZLWK
conditioned media, relative to the scrambled siRNA control (Fig. 3F). Therefore, these results
GHPRQVWUDWHWKDWVHFUHWHGFDWKHSVLQ6DOVRDFWLYDWHV,/Ȗ)/
5HFRPELQDQWFDWKHSVLQ6FOHDYHVDQGDFWLYDWHV,/Ȗ
7R H[SORUH WKH QDWXUH RI FDWKHSVLQ 6GHSHQGHQW ,/Ȗ FOHDYDJH UHFRPELQDQW FDWKHSVLQ 6 DQG
UHFRPELQDQW,/Ȗ)/ZHUHXWLOLVHG,QWKHVHH[SHULPHQWVWKHUHFRPELQDQW,/Ȗ)/ZDVH[SUHVVHG
ZLWKDQ1WHUPLQDO6802WDJVRWKDW,/Ȗ)/SURFHVVLQJFRXOGEHYLVXDOLVHGE\HOHFWURSKRUHVLV
:KHQ ERWK ,/Ȗ )/ DQG FDWKHSVLQ 6 ZHUH LQFXEDWHG WRJHWKHU DW  & ,/Ȗ )/ ZDV UDSLGO\
cleaved (within 5 min) into a protein of approximately 17 kDa (Fig. 4A). The identity of the cleaved
protein was interrogated by mass spectrometry and was found to have a mass of 17031, corresponding
H[DFWO\ WR WKHSUHGLFWHGPDVVRI WKH DFWLYH IRUP ,/Ȗ FOHDYHGEHWZHHQ UHVLGXHJOXWDPLQHDQG
serine 18 (figure 4A). This was also confirmed via N-terminal sequencing (data not shown).
7RGHPRQVWUDWH WKDW UHFRPELQDQWFDWKHSVLQ6FDQDFWLYDWH ,/Ȗ)/ERWKSURWHLQVZHUH LQFXEDWHG
together or separately for 10 min at 37 °C, and the products of this incubation were added to cultured
+D&D7 FHOOV :KLOVW WKH DGGLWLRQ RI ,/Ȗ )/ RU FDWKHSVLQ 6 GLG QRW KDYH DQ\ HIIHFW RQ ,/
secretion when added individually, the addition of both together caused a strong and significant
upregulation in IL-8 secretion, supporting previous evidence suggesting that cathepsin S potently
DFWLYDWHV,/Ȗ)/)LJ%)LQDOO\LWZDVLPSRUWDQWWRGHPRQVWUDWHWKDWFDWKHSVLQ6FRXOGDFWLYDWH
QDWLYHDVZHOODV UHFRPELQDQW ,/Ȗ)/:HKDYHVKRZQ WKDWSULPDU\NHUDWLQRF\WHVFRQVWLWXWLYHO\
H[SUHVVKLJKOHYHOVRI,/ȖSURWHLQGDWDQRWVKRZQ7RGHWHUPLQHZKHWKHUFDWKHSVLQ6FDQDFWLYDWH
WKH,/ȖFRQWDLQHGZLWKLQSULPDU\NHUDWLQRF\WHV+D&D7FHOOVZHUHLQFXEDWHGZLWKHLWKHUFDWKHSVLQ
S alone, the cytosolic fraction of primary keratinocyte alone or both cytosolic fraction and cathepsin
S. Whereas the addition of cathepsin S alone had no effect on IL-8 secretion, the addition of the
cytosolic fraction caused a strong up-regulation in IL-8 secretion (Fig. 4C). Importantly, IL-8
secretion was significantly higher when cells were incubated with both cathepsin S and cytosolic
fraction together, relative to cells incubated with the cytosolic fraction alone, suggesting that
FDWKHSVLQ 6 FDQ DFWLYDWH WKH QDWLYH ,/Ȗ SURWHLQ FRQWDLQHG ZLWKLQ WKH F\WRVRO RI SULPDU\
keratinocytes. Importantly, the addition of IL-36Ra completely abrogated this effect, demonstrating
that the observed effect was IL-36 dependent.
1HXWURSKLOSURWHDVHVGRQRWFOHDYH,/ȖLQWRWKHSRWHQW,/Ȗ6LVRIRUP
As discussed previously, a recent study by Henry et al. has shown that the neutrophil proteases
FDWKHSVLQ * QHXWURSKLO HODVWDVH DQG SURWHLQDVH  DOO FOHDYH ,/Ȗ ZLWK QHXWURSKLO HODVWDVH DQG
proteinase 3 increasing the activity of the protein (Henry et al., 2016). Thus it was important to assess
WKH UHOHYDQFH RI FDWKHSVLQ 6GHSHQGHQW ,/Ȗ LQ WKH FRQWH[W RI WKHVH QHXWURSKLO SURWHDVHV ,Q WKLV
VWXG\ 6802 WDJJHG ,/Ȗ ZDV LQFXEDWHG ZLWK UHFRPELQDQW FDWKHSVLQ * QHXWURSKLO HODVWDVH RU
SURWHLQDVHIRUPLQXWHVDW&7KHSURFHVVLQJRI,/ȖZDVWKHQYLVXDOLVHGE\HOHFWURSKRUHVLV
(Fig. 5A) and the identity of the cleaved products analysed by N terminal sequencing. From these
DQDO\VHV LW ZDV VKRZQ WKDW SURWHLQDVH  DQG FDWKHSVLQ * WUXQFDWHG ,/Ȗ WR < DQG 4
UHVSHFWLYHO\ ZKLOVW HODVWDVH JHQHUDWHG ERWK WUXQFDWLRQV 7R FRPSDUH WKH DFWLYLW\ RI WKHVH ,/Ȗ
WUXQFDWLRQV WR ,/Ȗ 6 WKH WUXQFDWLRQ SURGXFHG E\ FDWKHSVLQ 6 UHFRPELQDQW YHUVLRQV RI WKHVH
proteins were added to HaCaT cells and incubated for 24h (Fig. 5B). Here, it was shown that S18
induced a potent expression of IL-8 at all concentrations tested. In contrast the Y16 truncation and the
Q17 truncation had no effect on IL-8 expression. To support these data, HaCaT cells were incubated
ZLWK,/Ȗ)/DQGYDULRXVFRQFHQWUDWLRQVRIHLWKHUUHFRPELQDQWFDWKHSVLQ6FDWKHSVLQ*QHXWURSKLO
elastase or proteinase 3 (Fig. 5C). Here IL-8 secretion was markedly higher when the cells were
LQFXEDWHGZLWKFDWKHSVLQ6 IXUWKHUGHPRQVWUDWLQJ WKDW WKHSURGXFWRIFDWKHSVLQ6GHSHQGHQW ,/Ȗ
processing is a much more potent inducer of inflammation, relative to the products of neutrophil
SURWHDVHGHSHQGHQW,/ȖSURFHVVLQJ
7RLQYHVWLJDWHZKHWKHUWKHSURFHVVLQJRI,/ȖE\QHXWURSKLOSURWHDVHVKDVDGRZQUHJXODWRU\HIIHFW
RQ WKH DFWLYDWLRQRI ,/ȖE\FDWKHSVLQ6+D&D7FHOOVZHUH LQFXEDWHG IRUKUZLWK ,/Ȗ DQG
various concentrations of cathepsin S, both with and without the neutrophil proteases cathepsin G,
neutrophil elastase and proteinase 3 (Fig. 5D). In these experiments, the addition of neutrophil
proteases had a down-regulatory impact upon IL-8 expression, suggesting that neutrophil proteases
VHUYH WR GRZQUHJXODWH WKH DFWLYDWLRQ RI ,/Ȗ E\ FDWKHSVLQ 6 7R GHWHUPLQH ZKHWKHU QHXWURSKLO
SURWHDVHVDOVRGRZQUHJXODWHWKH,/H[SUHVVLRQLQGXFHGE\,/Ȗ6+D&D7FHOOVZHUHLQFXEDWHG
IRUKUZLWKYDULRXVFRQFHQWUDWLRQVRI,/Ȗ6ERWKLQWKHSUHVHQFHDQGDEVHQFHRIQHXWURSKLO
proteases (Fig. 5E). Again, the addition of neutrophil proteases reduced the IL-8 expression induced
E\,/Ȗ6,QFRQWUDVWZLWKSUHYLRXVVWXGLHVWKHVHGDWDVXJJHVWWKDWQHXWURSKLOSURWHDVHVVHUYHWR
GDPSHQ ,/ȖPHGLDWHG SURLQIODPPDWRU\ UHVSRQVHV E\ QRQVSHFLILFDOO\ SURFHVVLQJ ERWK WKH IXOO
length and active cytokines into inactive or only partially active truncations.
,/ȖDQG cathepsin S are strongly up-regulated in psoriasis
3UHYLRXV VWXGLHV KDYH VKRZQ WKDW ,/Ȗ 51$ LV VWURQJO\ XSUHJXODWHG LQ SVRULDWLF ELRSVLHV
Importantly, using the tape stripping methodology we were able demonstrate the corresponding
LQFUHDVHLQ,/ȖSURWHLQLQSVRULDWLFOHVLRQVUHODWLYHWRKHDOWK\FRQWUROV)LJ'+RZHYHUDVZH
ZHUHXQDEOHWRGLVWLQJXLVKWKHDFWLYHDQG LQDFWLYHIRUPVRI ,/Ȗ LQSVRULDWLFOHVLRQV WKHSUHVHQFH
DQG DFWLYLW\ RI WKH ,/ȖDFWLYDWLQJ SURWHDVH FDWKHSVLQ 6 E\ VNLQ UHVLGHQW FHOOV ZDV LQYHVWLJDWHG
&DWKHSVLQ 6 VHFUHWLRQ ZDV XSUHJXODWHG E\ WKH SVRULDVLV DVVRFLDWHG F\WRNLQHV 71)Į RU ,)1Ȗ LQ
SULPDU\ ILEUREODVWV DQG ZDV VWURQJO\ XSUHJXODWHG E\ ,)1Ȗ LQ SULPDU\ NHUDWLQRF\WHV )LJ $
&DWKHSVLQ 6 VHFUHWLRQ ZDV XSUHJXODWHG IXUWKHU E\ WKH DGGLWLRQ RI ERWK 71)Į DQG ,)1Ȗ WRJHWKHU
suggesting that these cytokines have a synergistic effect on cathepsin S expression. Neither IL-22 nor
IL-17 had an effect on cathepsin S secretion in these experiments.
Interestingly, a previous study using cathepsin S staining of biopsies has suggested that cathepsin S
may be upregulated in psoriatic lesions (30). To consolidate and quantify these findings, cathepsin S
protein levels were analysed in tape-strip samples acquired from the skin of psoriasis patients and
healthy controls. Here, cathepsin S levels and activity were significantly higher in the samples
acquired from psoriasis patients, suggesting that cathepsin S is up-regulated in psoriasis (Fig. 6B/C).
7RJHWKHU WKHVH GDWD VHUYH WR VKRZ WKDW ERWK FDWKHSVLQ 6 DQG ,/Ȗ DUH VWURQJO\ XSUHJXODWHG LQ
SVRULDWLF OHVLRQV LPSOLFDWLQJ WKH SURFHVVLQJ RI ,/Ȗ E\ FDWKHSVLQ 6 DV D FRPSRQHQW RI SVRULDWLF
inflammation.
,/Ȗ6FDXVHVK\SHUNHUDWRVLVLQDVNLQHTXLYDOHQWPRGHO
+DYLQJVKRZQ WKDWFDWKHSVLQ6DFWLYDWHV ,/ȖE\FOHDYLQJ LW LQWR ,/Ȗ6, and having shown
WKDWERWKFDWKHSVLQ6DQG,/ȖDUHVWURQJO\XSUHJXODWHGLQSVRULDVLVLWZDVLPSRUWDQWWRLQYHVWLJDWH
ZKHWKHU ,/Ȗ 6 GULYHV DQ\ FKDQJHV WKDW FXOPLQDWH LQ D SVRULDWLF SKHQRW\SH 7R DGGUHVV WKLV
UHFRQVWLWXWHGKXPDQHSLGHUPLVVNLQHTXLYDOHQWVZHUHWUHDWHGZLWKHLWKHUJURZWKPHGLDDORQH,/Ȗ
6 DQG ,/5D ,QWULJXLQJO\ WKH DGGLWLRQ RI ,/Ȗ 6 FDXVHG SVRULDVLIRUP FKDQJHV LQFOXGLQJ
stratum corneum thickening (hyperkeratosis) and epidermal cornification, the process whereby living
keratinocytes differentiate into non-living corneocytes (Fig. 7A). The thickness of the stratum
corneum was measured and shown to be significantly thicker in the S18 treated samples (Fig. 7B). IL-
8 secretion was also measured and shown to be significantly higher in the S18 treated samples,
suggesting that S18 drives pro-inflammatory and differentiation related changes in the epidermal
compartment (Fig. 7C). Importantly, these changes were blocked when the samples were treated with
WKH UHFHSWRU DQWDJRQLVW FRQILUPLQJ WKDW WKH HIIHFWV REVHUYHG ZHUH GHSHQGHQW RQ ,/Ȗ 6 7KLV
would explain the S18-induced thickening of the stratum corneum and concomitant loss of normal
differentiation pattern.
Discussion
Activated IL-1 family cytokines play a fundamental role in innate immune responses (31, 32). Thus,
the proteases involved in IL-1 cytokine activation are considered to be critical mediators of
inflammation. The importance of cytokine processing is highlighted by regulatory defects in caspase-
1 activation, which cause the recurrent, systemic and severe inflammatory episodes observed in
cryopyrin-associated periodic syndromes and other auto-inflammatory diseases such as Familial
Mediterranean Fever (2, 33). The correct balance of inflammation versus tissue maintenance is also of
particular relevance at cutaneous and epithelial borders, which are constantly exposed to complex
pathogenic and other environmental stresses. (34). This is evident in the rare auto-inflammatory
diseases DIRA and DITRA, where patients present with severe pustular skin eruptions due to
deficiencies in the receptor antagonists of IL-1 and IL-36 cytokines, respectively (35). As well as its
DSSDUHQW SDWKRORJLFDO UROH LQ LQIODPPDWLRQ ,/Ȗ LV DOVR LQYROYHG ZRXQG UHSDLU ZLWKLQ HSLWKHOLDO
compartments (9, 36, 377KXVDFRPSUHKHQVLYHXQGHUVWDQGLQJRI,/ȖDFWLYDWLRQLQWKHHSLWKHOLXP
LVLPSHUDWLYH,QWKLVLQYHVWLJDWLRQZHVKRZWKDWFDWKHSVLQ6LVWKHPDMRU,/ȖDFWLYDWLQJSURWHDVH
SURGXFHGE\VNLQUHVLGHQWFHOOW\SHVLPSOLFDWLQJWKLVSURWHDVHDVDFHQWUDOPHGLDWRURI,/ȖGULYHQ
cutaneous inflammation.
The mechanisms involved in the processing and secretion of IL-1 cytokines are of longstanding
academic interest, both because of their clinical significance and their evident complexity (38, 39).
Despite this interest, many of the processes involved are still poorly understood. In general, most IL-1
cytokines require 2 independent signals for secretion; an initial signal to induce expression of the
precursor and a second signal to drive cleavage and secretion (40). Most of the proteases that process
IL-1 precursors have been identified as cytosolic proteases and thus many of the current models of IL-
1 secretion indicate that processing occurs prior to secretion (21, 24, 41). In contrast, cathepsin S is
UHDGLO\ VHFUHWHG E\ D UDQJH RI VNLQ UHVLGHQW FHOOV VXJJHVWLQJ WKDW WKLV ,/ȖDFWLYDWLQJ SURWHDVH LV
DEXQGDQWO\H[SUHVVHGLQWKHH[WUDFHOOXODUVSDFHRIHSLWKHOLDOWLVVXH*LYHQWKDW,/ȖLVFRQVWLWXWLYHO\
expressed in keratinocytes and is further induced by microbial derived stimuli (42), we hypothesise
WKDW ,/Ȗ UHOHDVHG IROORZLQJ QHFURWLF FHOO GHDWK LV UDSLGO\ DFWLYDWHG E\ H[WUDFHOOXODU FDWKHSVLQ 6
7KHUHIRUH,/ȖPD\DFWDVDQLPSRUWDQWGDPDJHDVVRFLDWHGPROHFXODUSDWWHUQ'$03DNLQWR,/
ĮDQG,/PHGLDWLQJLQIODPPDWLRQDQGZRXQGUHSDLUZLWKLQHSLWKHOLDOFRPSDUWPHQWV43).
$OWKRXJKQHFURWLFFHOOGHDWKLVOLNHO\WREHDQLPSRUWDQWURXWHIRU,/ȖUHOHDVHDQGDFWLYDWLRQLWPD\
not be the only route. Many IL-1 cytokines have various mechanisms of release and thus it is probable
WKDW,/ȖDOVRKDVPXOWLSOHSDWKZD\VRIDFWLYDWLRQHVSHFLDOO\JLYHQWKDWFDWKHSVLQ6LVQRWVHFUHWHG
by the cells of many other tissues. Intriguingly, previous studies have shown that a fraction of
F\WRVROLFSUR,/ȕ LV VHTXHVWHUHG LQWRHDUO\ O\VRVRPHVDQGVHFUHWHG LQPRQRF\WHV 44). Given that
FDWKHSVLQ 6 LV FRQWDLQHG ZLWKLQ O\VRVRPHV LW LV WHPSWLQJ WR VSHFXODWH WKDW ,/Ȗ PD\ DOVR EH
sequestered into these secretory lysosomes. As lysosomal cathepsin S has been shown to activate IL-
Ȗ WKLV SURFHVV ZRXOG QRW RQO\ IDFLOLWDWH ,/Ȗ UHOHDVH EXW ZRXOG DOVR DOORZ IRU FRQFRPLWDQW
activation.
In a previous study by Henry et al., it was proposed that the neutrophil proteases elastase and
SURWHLQDVH DUH UHVSRQVLEOH IRU GULYLQJ ,/ȖGHSHQGHQW LQIODPPDWRU\ UHVSRQVHV 27). In more
GHWDLOLWZDVVXJJHVWHGWKDWWKHWUDXPDLQGXFHGQHFURVLVDWWKHHSLGHUPLVFDXVHGERWK,/ȖUHOHDVH
DQG QHXWURSKLO UHFUXLWPHQW FXOPLQDWLQJ LQ D QHXWURSKLO SURWHDVHGHSHQGHQW DFWLYDWLRQ RI ,/Ȗ
:KLOVW LW LV FOHDU WKDW WKH H[SRVXUH RI ,/Ȗ WR QHXWURSKLO SURWHDVHV UHVXOWV LQ WKH JHQHUDWLRQ RI
inflammatory responses, this research questions the relative importance of neutrophil protease-
GHSHQGHQW,/ȖFOHDYDJHLQDQin vivo setting, especially in light of the evidence herein. We show
WKDWWKHQHXWURSKLOSURWHDVHGHSHQGHQWFOHDYDJHRI,/ȖUHVXOWVLQWKHSURGXFWLRQRIWUXQFDWLRQVWKDW
DUHVLJQLILFDQWO\OHVVSRWHQWWKDQWKH6WUXQFDWLRQ0RUHRYHUZKHUHDVQHXWURSKLOGHSHQGHQW,/Ȗ
activation requires cellular recruitment followed by subsequent activation and degranulation (45),
FDWKHSVLQ6LVVWURQJO\H[SUHVVHGDW WKHVLWHRI,/ȖUHOHDVHDQGVRFDQLQVWDQWDQHRXVO\FOHDYHWKH
cytokine following its release. Thus, our data suggest that cathepsin S is the major protease
UHVSRQVLEOH IRU GULYLQJ ,/ȖGHSHQGHQW UHVSRQVHV LQ WKH VNLQ ,QWHUHVWLQJO\ QHXWURSKLO SURWHDVHV
GRZQUHJXODWH FDWKHSVLQ6 PHGLDWHG ,/Ȗ DFWLYDWLRQ VXJJHVWLQJ WKDW QHXWURSKLO SURWHDVHV PD\
DFWXDOO\ VHUYH WR GDPSHQ ,/ȖGULYHQ LQIODPPDWLRQ DW HSLWKHOLDO ERUGHUV 7KLV LV VXSSRUWHG E\
previous work in our laboratory, which demonstrated that neutrophil proteases activate IL-36Ra (46).
,Q UHFHQW VWXGLHV D UROH IRU ,/Ȗ LQ WKH GHYHORSPHQW RI SVRULDVLV KDV EHHQ SRVWXODWHG QRW OHDVW
EHFDXVH,/ȖKDVEHHQLGHQWLILHGDVRQHRIWKHPRVWVWURQJO\DQGVSHFLILFDOO\XSUHJXODWHGJHQHVLQ
psoriatic legions (12-147KHUHIRUHKDYLQJGHPRQVWUDWHGDUROHIRUFDWKHSVLQ6LQ,/ȖDFWLYDWLRQ
and having demonstrated that the expression levels of both proteins are elevated in psoriatic lesions, it
is highly likely that cathepsin S plays an important role in the pathogenesis of psoriasis. Furthermore,
JLYHQWKDWWKHSURGXFWRIFDWKHSVLQ6GHSHQGHQW,/ȖFOHDYDJHLQGXFHVVWUDWXPFRUQHXPWKLFNHQLQJ
K\SHUNHUDWRVLVLQDVNLQHTXLYDOHQWPRGHOWKHUHVXOWVKHUHLQVXJJHVWWKDWWKHDFWLYDWLRQRI,/ȖE\
cathepsin S may even be pivotal in driving a psoriatic phenotype. This hypothesis is supported by
previous work, which shows that IL-36 signalling is required in the Imiquimod-induced model of
psoriasis (17). Future studies, involving inducible cathepsin S overexpression or ablation in mice,
should provide further credence to these findings and thus provide a basis for future in vivo
investigations and therapeutic targeting.
$WSUHVHQWDQWL71)ĮDQWL,/DQGDQWL,/WUHDWPHQWRIVHYHUHSVRULDVLVSDWLHQWVKDVEHHQVKRZQ
to be of high clinical benefit, with higher efficacy regarding IL-23/IL-17 pathway blockage (47). IL-
ȖKDVEHHQVKRZQWREHLQGXFHGE\ERWK,/DQG71)DQGWKH\DFWV\QHUJLVWLFDOO\WRXSUHJXODWH
LWV H[SUHVVLRQ DQG VHFUHWLRQ  7KHUHIRUH WDUJHWLQJ GRZQVWUHDP ,/Ȗ FRXOG SRWHQWLDOO\ EH PRUH
beneficial than targeting IL-17 or TNF alone (48). Psoriasis susceptibility genes that impact on the
NF-kB pathway (e.g. CARD14, A20) have also been suggested to cause higher IL-36 expression and
activity (49). Once expressed and activated, IL-36 acts in a positive feedback manner activating skin
tissue cells including keratinocytes and fibroblasts. Thus, under circumstances of limited IL-36Ra
availability and/or excessive activating cathepsin S, IL-36 could be a central molecule, serving to
maintain a T cell-independent psoriatic skin phenotype within the epidermal compartment. Although
IXUWKHU ZRUN LV UHTXLUHG WR FODULI\ WKH H[WHQW WR ZKLFK ,/Ȗ FRQWULEXWHV WR WKH GHYHORSPHQW RI
SVRULDVLV WKHVH GDWD LQGLFDWH WKDW ,/Ȗ FRXOG UHSUHVHQW PDMRU WKHUDSHXWLF WDUJHWV LQ LWV WUHDWPHQW
Furthermore, although previous clinical trials targeting cathepsin S have been discontinued (50), these
studies were conducted based on the role of cathepsin S in MHCII antigen presentation. Therefore, it
may be of benefit to revisit this therapeutic target, given the evidence that cathepsin S is required for
WKHDFWLYDWLRQRI,/Ȗ
7R FRQFOXGH WKLV VWXG\ GHPRQVWUDWHV WKDW FDWKHSVLQ 6 LV WKH PDMRU SURWHDVH RI ,/Ȗ DW EDUULHU
tissues. These findings are not only significant from a mechanistic perspective, but may also provide
QHZWKHUDSHXWLFVWUDWHJLHVIRUWKHWUHDWPHQWRISVRULDVLVHVSHFLDOO\DVERWK,/ȖDQGFDWKHSVLQ6DUH
strongly up-regulated in psoriatic lesions. These results now pave the way for in vivo studies to
LQYHVWLJDWH WKH H[WHQW WR ZKLFK FDWKHSVLQ 6 DFWLYDWLRQ RI ,/Ȗ FRQWULEXWHV WR WKH PDLQWHQDQFH RI
epithelial homeostasis, and to the initiation and development of psoriasis.
Methods
Reagents and antibodies
The protease inhibitors E64 and cathepsin S inhibitor (CATSi) were purchased from Merck Millipore
(Billerica, MA). 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) was obtained
from Sigma (Poole, UK). Human recombinant Cathepsin S was purchased from Bio Vision (Milpitas,
CA). Cathepsin S siRNA and scrambled siRNA was purchased from Dharmacon (Lafayette, CA).
For Western-blot analysis, the primary antibodies were a rabbit anti-SUMO antibody (AB14405;
AbCam, Cambridge, UK), a mouse anti-GAPDH antibody (GT239; Genetex, Irvine, CA), a mouse
DQWL/$03DQWLERG\6&6DQWD&UX]%LRWHFKQRORJ\6DQWD&UX]&$DQGDJRDWDQWL,/Ȗ
antibody BAF2320; R&D Systems; Minneapolis, MN). The HRP-conjugated secondary antibodies
used were an anti-rabbit IgG antibody (64405; Southern Biotech; Birmingham, AL), an anti-mouse
IgG antibody (A9917; Sigma) and an anti-goat antibody (A3919; Sigma). Human Recombinant pro-
,/ȕZDVSXUFKDVHG IURP6LQR%LRORJLFDO %HLMLQJ&KLQDDQGKXPDQ UHFRPELQDQWFDVSDVHZDV
SXUFKDVHGIURP%LRYLVLRQ0LOSLWDV&$7KHKXPDQUHFRPELQDQWSURWHLQV71)Į,)1Ȗ ,/DQG
IL-22 were all purchased from R&D Systems.
Generation of recombinant proteins
To generate IL-36 fusion proteins possessing N-terminal SUMO domains, cDNA of full length IL-
Ȗ ,/5D9DQG ,/Ȗ6SURWHLQVZHUH FORQHG LQWR D&KDPSLRQS(76802H[SUHVVLRQ
vector (Invitrogen, UK). Proteins were subsequently expressed in BL21-CodonPlus (DE3)-RIL E. coli
overnight at 25°C and soluble proteins purified via Ni2+-affinity and size exclusion chromatography.
Proteins used for stimulations were purified by Ni2+-affinity chromatography prior to overnight
cleavage of N-terminal SUMO by the Ulp1 protease, followed by subsequent ion exchange and size
exclusion chromatography into 20mM Tris pH7.4, 300mM NaCl.
Caspase-1 activity assay
JRI6802WDJJHGUHFRPELQDQW ,/Ȗ6ELRORJLFDOO\DFWLYHIRUP ,/ȖIXOO OHQJWK)/RU
SUR,/ȕ DOO SRO\KLVWLGLQH WDJJHG ZHUH GLOXWHG LQ DVVD\ EXIIHU P0 +(3(6 S+  P0
NaCl, 0.1% CHAPS, 1mM EDTA, 10% glycerol, 10mM DTT) and incubated with recombinant
caspase-1 (4 units) at 37°C for 6 hr.
Gel electrophoresis and Western blotting
In preparation for Western blot analysis, samples were diluted in sample buffer (50mM Tris HCl pH
6.8, 2% SDS, 10% glycerol, 0.02 % bromophenol blue) and heated at 90°C for 5 min. Samples were
resolved on a 15% acrylamide gel and proteins transferred to a nitrocellulose membrane. Specific
proteins were detected using anti-SUMO, anti-GAPDH or anti-LAMP-1 antibodies (all 1 µg/ml.
Subsequently, blots were incubated with either HRP-labelled anti-mouse IgG antibody (for GAPDH
and LAMP-1) or HRP-labelled anti-rabbit IgG antibody (for SUMO; all 1µg/ml). Proteins were
visualized using enhanced chemiluminescence reagents (GE Healthcare; Little Chalfont, UK).
Cells, cell lines and skin equivalents
Primary keratinocytes and fibroblasts were purchased from Promocell (Heidelberg, Germany) and
Lonza (Castleford, UK) respectively. A549 cells, HaCaT cells and primary fibroblasts were cultured
in FCS-supplemented culture medium (DMEM), containing 100 U penicillin/ 0.1 mg/ml streptomycin
and 10% FCS (all Life technologies). Primary keratinocytes were cultured in keratinocyte growth
medium-2 (Promocell). Epidermal skin equivalents (EpiSkin; Lyon, France) were purchased from
SkinEthics and maintained according to the manufacturer’s protocol. Skin equivalents were treated on
GD\  ZLWK HLWKHU FRQWURO PHGLPDFOHRG D ,/Ȗ 6 RU ,/Ȗ 6 DQG ,/5D IRU (?KRXUV
Following incubation, supernatants were removed and frozen at -80°C. Skin reconstructs were fixed
in 4% formaldehyde for 1 hr at RT, removed from their inserts and embedded in paraffin. Sections
ZHUH FXW DW  ȝP WKLFNQHVV RQ D /HLFD 50 PLFURWRPH /HLFD :HW]ODU *HUPDQ\ WUDQVIHUUHG
onto PlusFrost microscope slides (Solmedia UK) and subjected to HE-staining at RT. Prior to
analysis, the operator was blinded to the identity of the samples. Slides were imaged using a Leica
Aperio AT2 scanner and analysed using Image J (Bethesda, MA).
Cell lysis and fractionation
Whole cell lysates, lysosomal extracts and cytosolic extracts were generated from 107 growing cells.
Cells were harvested by centrifugation at 800g. To generate whole cell lysates, cells were resuspended
in 500µl cell extract buffer (20mM Hepes, pH 7.5, 10mM KCl, 1mM EDTA, 1mM EGTA, 1mM
DTT) and incubated for 20 min on ice. Cells were then transferred to a Dounce-type homogeniser and
homogenised with 15 strokes of a B-type pestle. Lysates were centrifuged at 15,000 g for 30 min to
remove cellular debris and frozen at -80°C. To generate cytosolic and lysosomal extracts, cells were
resuspended in 500µl cell fractionation buffer (Tris HCl, pH 7.4, 0.25M sucrose, 1mM EDTA, 1mM
EGTA, 1mM DTT), transferred to a Dounce-type homogeniser and homogenised with 15 strokes of a
B-type pestle. The homogenate was centrifuged at 1000 g for 10 min to remove the nuclei and other
cellular debris. The supernatant was then collected and centrifuged at 15,000 g to separate the
lysosome from the cytosol. The cytosol was then frozen down at -80°C and the lysosome resuspended
in cell extract buffer 500µl. Following a 20 min incubation on ice and repeated freeze thaw cycles, the
lysosomal fraction was centrifuged at 15,000 g for 30 min and supernatants frozen at -80°C.
IL-36 cleavage assay
For activity assay experiments, HaCaTs were plated at 105 cells/well (24-well plate) in complete
culture media, and incubated for 24 hours. The media was then removed and replaced with OptiMEM
(Life technologies). For most activity assay experiments, indicated treatments were added in
conjunction with OptiMEM and cells incubated for 24 hr at 37°C. For activity assay experiments
involving protease inhibitors, lysosome fractions were preincubated with E64, AEBSF or CATSi for 3
hr at 4°C before being added to HaCaT cells. For the activity assay experiments involving cell
supernatants, A549 cells, primary keratinocytes or primary fibroblasts were plated at 0.5x105
cells/well (6-well plate) in complete culture media. Once confluent, the media was replaced with
OptiMEM and cells incubated for a further 24 hr. Following incubation, the conditioned media was
removed and frozen at -80°C. In preparation for the activity assay, the conditioned media was
supplemented with 0.1mM DTT. The activity assay for these experiments was performed as
previously described, the only difference being that the media on the HaCaT cells was replaced with
the conditioned media and not OptiMEM. Following incubation, cell supernatants were removed and
frozen at -80°C.
siRNA knockdown
A549 cells (0.5 x 106/well) were plated in 6-well plates and incubated for 24 hr at 37°C in culture
media without penicillin/streptomycin. For each well, 50pmol Cathepsin S siRNA or scrambled
siRNA was diluted in 200µl of OptiMEM and incubated at room temperature for 5 minutes. 8µl
Lipofectamine (Thermo Scientific, Waltham, MA) was also diluted in in 200µl of OptiMEM and
incubated at room temperature for 5 min. The lipofectamine and siRNA preparations were then
combined and incubated for 20 min at room temperature. 1.6ml of culture media (without penicillin/
streptomycin) was added to the lipofectamine/siRNA mixture. The culture media was removed from
each well and the siRNA preparations added. Cells were incubated for 24 hr at 37°C. The culture
media was then replaced with OptiMEM and cells incubated for a further 48 hr. Following incubation,
cell supernatants were removed and frozen at -80°C.
ELISA
Supernatants were analyzed for IL-8 protein using a specific ELISA kit from Biolegend (San Diego,
CA). Supernatants and lysates were analyzed for cathepsin S protein using a specific ELISA kit from
R&D Systems. ELISA were performed following the manufacturer’s instructions. The lower limits of
accurate detection for IL-8 and cathepsin S were 15.6 pg/ml. For the conditioned media experiments,
levels of IL-8 in the media prior to the activity assay were deducted from levels recorded after the
activity assay to give an accurate measure of de novo IL-8 synthesis.
Molecular mass confirmation by LC-MS
1 µg protein was loaded onto a MassPREP micro desalting column (Waters; Elstree, UK) and washed
for 5 min with 10% acetonitrile/ 0.1% formic acid. Following a 1 min gradient to 85% acetonitrile/
0.1% formic acid the protein was eluted into a Xevo G2-XS QToF (Waters) using electrospray
ionisation for molecular mass measurement.
Tape stripping
All samples were collected with written informed consent in place of the patients, taken in
accordance with the Declaration of Helsinki (REC 14/NE/1199). Healthy volunteers were also
recruited from the University of Leeds and written consent was also sought (BIOSCI09-001). The
severity of lesions was clinically assessed before sample collection using D-squame adhesive discs of
3.8 cm² (Cuderm; Dallas TX). Samples from non-lesional skin were taken preferably from the ventral
lower arm area. Location of lesional samples was guided by lesion appearance. Only non-erosive,
non-oozing lesions were tape stripped. The tapes were placed on the skin for 5 sec with gentle
pressure. The first tape was discarded and 10 subsequent tapes collected were put in an empty
container and immediately stored on dry ice for transportation or storage at -80°C until processing for
protein extraction. To extract the protein, tapes were placed in lysis buffer (20mM Tris pH 7.4,
150mM NaCl, 1mM DTT, 5mM EDTA, 1mM PMSF, 1% Triton X-100) for 30 min at 4 °C. Samples
were sonicated for 3 times 20 sec with a 20 sec interval on ice between each sonication. Samples were
centrifuged for 10 min at 15,000g. Supernatants were removed and frozen at -80°C.
BCA
Total protein concentrations were quantified using a reducing agent compatible BCA assay
(Biovision). The BCA assay was performed following the manufacturer’s instructions.
Cathepsin S activity assay
Samples (1µg total protein/ sample) were analysed for cathepsin S activity using a fluorometric kit
obtained from Biovision. The activity assay was performed following the manufacturer’s instructions.
Statistics
Statistical analysis was performed using the software Graphpad Prism 6. Data were analyzed by one-
way ANOVA to determine overall differences and a Tukey post-hoc test was performed to determine
statistically significant differences between treatment groups. Data were also analysed using an
unpaired t-test.
Abbreviations
AEBSF- 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
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Figures
)LJ(SLWKHOLDOFHOOSURWHDVHVDFWLYDWH,/ȖHaCaT cells (105/well) were incubated with media
DORQH8,/Ȗ)/ȖQ0,/Ȗ66Q0RUERWK,/Ȗ6DQG,/5D5$
50nM) for 24 hr (A,QDGGLWLRQJRI6802WDJJHGUHFRPELQDQW,/ȖVX,/Ȗ,/Ȗ)/RU
SUR,/ȕ DOO SRO\KLVWLGLQH WDJJHG ZHUH LQFXEDWHG ZLWK UHFRPELQDQW FDVSDVH DW & IRU  KU
These samples were then analysed by Western blot using an anti-His-HRP antibody (B). A protein
marker lane on each gel was used to determine molecular weight. HaCaT cells (105/well) were also
LQFXEDWHG IRU  KU ZLWK PHGLD DORQH ,/Ȗ )/ ZKROH FHOO O\VDWHV IURP $ FHOOV : RU D
FRPELQDWLRQRI,/Ȗ)/DQGZKROHFHOOO\VDWHVZLWKDQGZLWKRXW,/5DQ0C).
HaCaT cells (105ZHOO ZHUH LQFXEDWHG IRU  KU ZLWK ,/Ȗ )/ Q0 WKH F\WRVROLF IUDFWLRQ RI
$ FHOOV F D FRPELQDWLRQ RI ,/Ȗ )/ DQG F\WRVRO ZLWK DQG ZLWKRXW ,/5D Q0 WKH
O\VRVRPHIUDFWLRQIURP$FHOOV/RUDFRPELQDWLRQRI,/Ȗ)/DQGO\VRVRPHZLWKDQGZLWKRXW
IL-36Ra (E). HaCaT cells (105ZHOO ZHUH DOVR LQFXEDWHG ZLWK ,/Ȗ )/ Q0 WKH O\VRVRPH
fraction of either HaCaT cells (F), primary fibroblasts (G) or primary keratinocytes (H), or a
FRPELQDWLRQRI ,/Ȗ)/DQG O\VRVRPHZLWKDQGZLWKRXW ,/5D Q07KHVXSHUQDWDQWV IURP
these experiments were analysed for the presence of IL-8 using cytokine-specific ELISA (A, C, E, F,
G, H). The cytosolic and lysosomal fractions from A549 cells were analysed by Western blot using
HLWKHU DQ DQWL/$03RU DQWLĮ WXEXOLQ DQWLERG\ D). A one-way ANOVA was used to determine
statistical significance of differences between treatment groups. *, p < 0.05; **, p < 0.01, ***, p <
0.001, ****, p < 0.0001. Data shown are mean ± SEM (n=3).
Fig 2. Activation of IL-36Ȗ is dependent on cathepsin S. HaCaT cells (105/well) were incubated for
 KU ZLWK PHGLD DORQH ,/Ȗ 6 6 Q0 RU ,/Ȗ )/ )/ Q0 ZLWK WKH O\VRVRPH
IUDFWLRQRI$FHOOVDOOZLWKDQGZLWKRXWWKHF\VWHLQHSURWHDVHLQKLELWRU(ȝ0RUWKHVHULQH
LQKLELWRU$(%6)ȝ0A ,Q WKHVHH[SHULPHQWV WKH LQKLELWRUVZHUHSUHLQFXEDWHGZLWK WKH ,/Ȗ
6RUO\VRVRPHDW&IRUKUWRJLYHDQLQLWLDOFRQFHQWUDWLRQRIP0IRU$(%6)DQGȝ0IRU
E64. HaCaT cells (105ZHOOZHUHDOVRLQFXEDWHGIRUKUZLWKPHGLDDORQH,/Ȗ6Q0RU
,/Ȗ )/ Q0 ZLWK WKH O\VRVRPH IUDFWLRQ RI $ FHOOV DOO ZLWK DQG ZLWKRXW WKH FDWKHSVLQ 6
inhibitor (CATSi; 100ng/ml; B $JDLQ WKH &$76L ZDV SUHLQFXEDWHG ZLWK WKH ,/Ȗ 6 RU
O\VRVRPHDW&IRUKUWRJLYHDQLQLWLDOFRQFHQWUDWLRQRIȝJPO7RLQKLELWH[SUHVVLRQRIFDWKHSVLQ
S within A549 lysosomes, A549 cells were transfected with cathepsin S siRNA (CATS) or scrambled
siRNA (SCRAM; both 25nM) for 24 hr and lysosome fractions extracted. The lysosome fractions
were analysed for the presence of cathepsin S using a specific ELISA (C). Finally, HaCaT cells
(105/well) were incubated for 24 hr with the lysosome of SCRAM-transfected or CATS-transfected
$ FHOOV ERWK ZLWK RU ZLWKRXW ,/Ȗ )/ Q0D). The supernatants from these experiments
were analysed for the presence of IL-8 using cytokine-specific ELISA (A, B, D). A one-way ANOVA
(A, B, D) or unpaired t-test (C) was used to determine statistical significance of differences between
treatment groups. **, p < 0.01, ****, p < 0.0001. Data shown are mean ± SEM (n=3).
)LJ  6HFUHWHG FDWKHSVLQ 6 DFWLYDWHV ,/Ȗ A549 cells, primary keratinocytes, or primary
fibroblasts were incubated in 6-well plates until confluent, at which point the media was replaced with
OptiMEM and cells incubated for a further 24 hr. Supernatants were analysed for the presence of
cathepsin S using cytokine-specific ELISA (A). HaCaT cells (105/well) were incubated for 24 hr with
0.1mM DTT-supplemented conditioned media from A549 cells (B), primary keratinocytes (C),
primary fibroblasts (D &HOOV ZHUH LQFXEDWHG ZLWK HLWKHU PHGLD DORQH ZLWK ,/Ȗ )/ Q0 RU
ZLWKERWK,/Ȗ)/DQG,/5DQ06XSHUQDWDQWVZHUHDQDO\VHGIRUWKHSUHVHQFHRI,/XVLQJ
cytokine-specific ELISA (B, C, D). To inhibit expression of cathepsin S, A549 cells were transfected
with cathepsin S siRNA (CATS) or scrambled siRNA (SCRAM; both 25nM) for 24 hr and the
supernatants extracted. Supernatants were analysed for the presence of cathepsin S using a specific
ELISA (E). Finally, HaCaT cells (105/well) were incubated for 24 hr with the supernatants from
6&5$0WUDQVIHFWHGRU&$76WUDQVIHFWHG$FHOOV HLWKHUZLWKRUZLWKRXW ,/Ȗ)/ Q0F).
The supernatants from these experiments were analysed for the presence of IL-8 using cytokine-
specific ELISA (F). A one-way ANOVA (B, C, D, F) or unpaired t-test (E) was used to determine
statistical significance of differences between treatment groups. *, p < 0.05, **, p < 0.01. Data shown
are mean ± SEM (n=3).
)LJ5HFRPELQDQWFDWKHSVLQ6FDQFOHDYHDQGDFWLYDWH,/ȖȝJRI6802WDJJHG,/ȖZDV
LQFXEDWHG ZLWK QJ RI UHFRPELQDQW FDWKHSVLQ 6 DW Û& IRU  PLQXWHV 6HYHUDO WLPH SRLQWV ZHUH
taken and analysed by coomassie stained SDS-PAGE gel. Diagram depicts the truncation generated
by cathepsin S cleavage identified by mass spectrometry analysis (A). HaCaT cells (105/well) were
LQFXEDWHGIRUKUZLWKPHGLDDORQH,/ȖQ0FDWKHSVLQ6&DW6QJPORUDFRPELQDWLRQ
RI,/ȖDQGFDWKHSVLQ6B). In addition, HaCaT cells were incubated with media alone, the cytosol
of keratinocytes, cathepsin S (10ng/ml), a combination of cytosol and cathepsin S or a combination of
cytosol, cathepsin S and IL-36Ra (C). Supernatants were analysed for the presence of IL-8 using a
specific ELISA (B, C). A one-way ANOVA was used to determine statistical significance of
differences between treatment groups. *, p < 0.05. Data shown are mean ± SEM (n=3).
)LJ1HXWURSKLOSURWHDVHVGRQRWFOHDYH,/ȖLQWRWKHSRWHQW,/Ȗ6ELRDFWLYHIRUPȝJ
RI6802WDJJHG,/ȖZDVLQFXEDWHGZLWKSJRIUHFRPELQDQWFDWKHSVLQ*QHXWURSKLOHODVWDVHRU
SURWHLQDVHDWÛ&IRUPLQXWHV6DPSOHVZHUHDQDO\VHGE\FRRPDVVLH VWDLQHG6'63$*(JHO
Diagram depicts the truncation generated by cleavage identified by mass spectrometry analysis (A).
HaCaT cells (105ZHOOZHUHLQFXEDWHGIRUKUZLWKPHGLDDORQH8,/Ȗ)/,/Ȗ<,/
Ȗ 4RU ,/Ȗ 6 DOO HLWKHU Q0 Q0 RU Q0B). HaCaT cells (105/well) were also
LQFXEDWHG ZLWK ,/Ȗ )/ Q0 DQG YDULRXV FRQFHQWUDWLRQV RI HLWKHU UHFRPELQDQW FDWKHSVLQ 6
cathepsin G, neutrophil elastase or proteinase 3 for 24hr (C). In addition, HaCaT cells (105/well) were
LQFXEDWHGIRUKUZLWK,/ȖQ0DQGFDWKHSVLQ6Q0Q0ERWKZLWKEODFNOLQHDQG
without (red line) the neutrophil proteases cathepsin G, neutrophil elastase and proteinase 3 (all 1nM;
D). HaCaT cells (105ZHOO ZHUH DOVR LQFXEDWHG IRU  KU ZLWK ,/Ȗ 6 Q0 ERWK ZLWK
(black line) and without (red line) the neutrophil proteases cathepsin G, neutrophil elastase and
proteinase 3 (all 1nM; E). Supernatants were analysed for the presence of IL-8 using a specific ELISA
(B, C, D, E). A two-way ANOVA was used to determine statistical significance of differences
between NS and other treatment groups. **** p < 0.0001. Data shown are mean ± SEM (n=3).
)LJ  ,/Ȗ SURWHLQ H[SUHVVLRQ DQG FDWKHSVLQ 6 DFWLYLW\ DUH HOHYDWHG LQ SVRULDVLV Primary
fibroblasts (white bar) or primary keratinocytes (black bar; both 106/well) were incubated for 48hr
ZLWKHLWKHU71)Į,)1Ȗ,/RU,/DOOQJPODQGVXSHUQDWDQWVDQDO\VHGIRUWKHSUHVHQFHRI
cathepsin S using a specific ELISA (A). In addition, elutes were acquired from the skin of healthy and
psoriasis patients using tape stripping methodology. Samples were analysed for the presence of
cathepsin S using a specific ELISA (B). Cathepsin S activity was measured using a fluorometric
cathepsin S activity assay (C 6DPSOHV ZHUH DOVR DQDO\VHG E\ :HVWHUQ EORW XVLQJ DQ DQWL,/Ȗ
antibody (n=5; D). For Western blot analysis, samples were normalised so that equal amounts of total
protein were loaded in each well. A one-way ANOVA was used to determine statistical significance
of differences between treatment groups. *, p < 0.05. Data shown are mean ± SEM (n = 3 unless
previously stated).
)LJ,/Ȗ6 WKHPDLQSURGXFWRIFDWKHSVLQ6FOHDYDJH LQGXFHVK\SHUNHUDWRVLV LQDVNLQ
equivalent model. Reconstructed human epidermis skin equivalents were grown for 96 hours in
JURZWK PHGLXP HLWKHU XQWUHDWHG 8 RU FRQWDLQLQJ ,/Ȗ 6 Q0 ZLWK DQG ZLWKRXW ,/5D
(100nM). Sections were stained with H&E and annotated in ImageJ software to display epidermal
thickness (A). Stratum corneum thickness was measured from 4 points along each skin slice (n=4)
(B). Supernatants were also collected at the end of the experiment and analysed for the presence of
IL-8 using a specific ELISA (C). A one-way ANOVA was performed to determine statistical
significance of differences between treatment groups. *, p < 0.05, **** p < 0.0001. Data shown are
mean ± SEM.







